Tracheal resec tion and primary anasto mos is is the treatment ofchoice fo r a sho rt-segment stenos is. However, the procedure does carry the risk of two po tentially fata l complicatio ns: anastomos is breakdow n and leak. We describe the case ofa 67-year-old man who was treated for a S-cm trachea l stenosis secondary to a prolonge d intubation and multiple tracheostomies. The pat ient W Ide/went a tracheal resection and primary anasto mosis. The anasto mosis was reinf orced withfibrin sealant, which created an airtight seal. The pat ient was extubated postope ratively, and he healed witho ut complication. Fibrin sealant is a convenient, safe, and effective material fo r reinfo rcing anastomotic suture lines.
Introduction
Postintubation tracheal injury is the most common indication for tracheal resection and reco nstruc tio n. Common postoperative complications include suture -line granulation, dehi scence of the anasto mos is, resteno sis, vocal fold paralysis, tracheomalacia, hemor rhage, and infection .The incidence of one of these co mplica tions-suture -line granuloma-has decreased since the use of abso rbable synthetic sutures (e.g ., Vicryl) and the submucos al placement of sutures has become more com monplace.' Th e incidence of the other com plications has rem ained co nstant.
Case report
A 67-year-old man who experienced a tracheal stenosis after a prolonged int ubation and trac heosto my decannul ation ca me to the oto laryngo logy servi ce with a co mplaint of stridor at rest. A head and neck exa mination revealed the presence of a well-hea led trach eostom y scar. Flexible fiberoptic laryn goscopy revealed that both voca l folds were mob ile. Com puted tomography of the neck revealed a proxim al trac hea l stenos is. Flex ible bronchoscopy demonstrate d tracheomalacia and a collapse of the trachea at the ste notic segment (fig ure I) . The patient was schedu led for a diag nos tic rigi d bro nchoscopy and primary resection and repair of the tracheal stenosis.
Intraoperative ly, the rigid bronchoscopy revealed the presence of a 2.5-c m proxi mal steno tic seg ment (figure 2) . Th e patient underwent oro trac hea I intubation, neck exp loration, and trach eal dissection. Th e stenotic segment was isolated. It invo lved the dis tal cr ico id cartilage and proximal trachea (Grillo type II). Th e stenotic segment was circumferentially mobi lized and resec ted. The oro tracheaI tube was repl aced with a trach eal tube through the neck incision. The pos terio r wall was reconstru cted with interrupted Vicryl sutures (fig ure 3 ). Aft er the posterior wall was rep aired , the patient was reintubated oro trachea lly and the anteri or wall was repaired with interru pted Vicry l sutures. Th e suture line was reinforced with fibrin glue laced with gentamic in (fig ure 4 ). The strap muscles were closed at the midl ine, and the ski n was closed afte r the subc uta neous space was drained. A neck flex ion stitch was app lied, and the patient was ex tubated.
Postoperative bronchoscopy showe d a good airway with no gra nulatio n tissue. Te n mon ths postoperatively , the patient still maintained a goo d airway (figure 5).
Discussion
Tracheal resection and anas tomos is is a tech nica lly difficult ope ratio n that carries the risk of life -threa tening co mplications, inclu ding suture -line dehiscence, innominate artery eros io n, and wound infec tion.!" Grill o et al reported a large series in which the incid ence of tracheal wound dehisce nce or tracheal stenos is was 2.2% for tracheotracheal anasto moses, 6.1% for crico trachea l anas-For further information on the Digital Strobe, contact Kay Elemetrics or a local representative.
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Kay's stroboscopy systems complement a complete line of instrumentation for the voice lab including the most widely used acoustic and aerodynamic analysis systems. Kay offers extensive product support that includes worldwide representatives, toll-free phone support, educational courses and workshops, and a comprehensive Web site.
Kay's Digital Strobe, an innovative digital video endoscopy! stroboscopy system, sets a new standard for image quality and convenience for stroboscopy and endoscopy examination viewing and recording.
With the Digital Strobe, patient exams are recorded directly to computer storage media.The resulting image quality is equivalent to professional broadcast standards, and superior to previous recording technology that relied on SVHS video recorders .
Digitizing the video examination provides other benefits as well. Examinations can be located and viewed instantaneously without the need to rewind or fast forward to the start of the exam. In addition, two exams can be loaded and played side by side; this unique feature greatly facilitates exam comparisons.
The system is provided with a sophisticated patient database and a report generator which is automatically formatted as a Microsoft" Word document. The report includes patient information, a summary of key examination findings, still images, and an AVI video clip from the exam-this report can be printed or mailed electronicallyto colleagues and referring physicians. to mose s, and 8.0 % for thyrotracheal anastomoses. I They also reported that innominate artery erosion occurred in five of the ir 503 pati ents ( 1.0%), three of whom died (0.6%), and that major wound infections occurred in 15 patients (3.0 %) .
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Reinforcing the suture line with fibrin glue adds strength to the line, creates an airtight seal, isolates the inn omin ate artery from the an astom osis, and pro vides a medium for the local deli very of antibiot ics.
Fibrin sea lant (Tisseel; Baxter Healthc are Corp .; Glendale, Calif. ) contai ns fibrin ogen (a sea ler prote in) as its main ac tive ingredient. It also co ntains thrombin , calcium chl oride, and a fibrin olysis inhibitor (aprotinin). The two recon stituted component s-the sea ler protein and the thr ombin solutions-are mixed and applied topically. Mixing the sealer protein and the thrombin solutio ns produces a viscous solution that form s an elasti c coagulum when it set s. Thrombi n is a high ly specific pro tease that tran sfo rms the fibrinog en contained in the seal er protein co ncentrate into fibrin . The thrombin is part ly minimized during the Tisseel manufactu ring process, whic h incorporates a two-step vapor-hea ting process that inactivates viruses .
In conclusio n, given the potential devastatin g complications of suture dehi scence and wound infec tion and the appare nt safe ty of fibrin glue, we believe that fibrin glue appears to be a wor thw hile method of rein forcing a tracheal anastomosis line. It reduces the risk of leak s, anastomosis deh iscence , innominate eros ion, and wound infection. Even so, a large prospective study is need ed to co nfirm its efficacy . Rat Hepatocyte DNA Repair Assay MicronucleusTest (Mice) DominantLethalTest (Mice) Long-term carcinogenicity studies in mice and rats have been compieted for ciprofloxacin. After daily oral doses of 750 mglkg(mice) and 250mglkg (rats) were administered for upto 2 years, there was no evidence that ciprofioxacin hadanycarcinogenicor tumori genic effects in these species. No long termstudiesof CIPRO' HCOTIC suspension have beenperformed to evaluate carcinogenic potential. Fertility studies performed in rats at oral doses of clprotloxacin upto 100 mglkg/day revealed no evidence of impairment. Thi s would beover 1000times the maximumreco mmended clinical dose of ototopical ciprofloxacin basedupon body surface area, assuming total absorption of ciprofloxacin from the ear of a patienttreatedwith CIPRO' HCOTICtwice per day. Long term studies have not beenperformedto evaluate thecarcin ogenic potenti alor theeffect on fertility of topical hydrocortisone. Mut agenicity studieswith hydrocortisonewere negative. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproducti onstudieshave beenperf orm ed in rats and mi ceusing oral doses of up to 100 mglkg and IV doses upto 30 mglkg and have revealed no evidence of harm to the fetus asa result of ciprofloxacin. In rabbits, clpronoxacln (30 and100 mglk g orally)producedgastrointestinal disturbances resulting in mat ernal weight loss andan increased incid ence of abortion, but no teratogenicity was observed at eit her dose. After intravenousadministrationof doses upto20 mglkg, no maternal toxicity was produced In the rabbit, and no embryotoxicity or teratogenicity was observed. Corticosteroi dsaregenerall y teratogenic in laboratoryanimalswhen administered systemicallyat rel ati vel y low dosage levels. The more potentcorticosteroidshave been shown to beteratogenic afterdermalapplication in laboratoryanimals. Animal reproductionstudies havenotbeenconductedwithCIPRO' HCOTIC. Noadequa teand well controlled studies have been performed in pregnantwomen. Cautionshould beexercised when CI PRO' HCOTICis usedby a pregnantwoman. Nursing Mot hers: Ciprofloxacin is excreted in human milk wi th systemicuse. It is not known whether ciprotloxacin is excreted in humanmilk following topical oticadministration. Because of the potent ial for serious adverse reactions in nursing infants, a decision shoul d bemade whetherto discontinue nursing or to discontinuethe drug, taking into account theimportance of the drug to the mother. Pediatric use: The safetyand effi cacy of CIPRO' HC OTIC have beenestablishedin pediatric patients 2 years and older (131 patients) in adequate and well-controlled clinical trial s. Although nodataareavailableon patients less thanage 2years, thereareno known safetyconcernsor differences in thedisease process inthis80Pulation which would preclude useof this product in patients oneyear and older . See DOSA EAND ADMINISTRATION . ADVERSE REACTIONS InPhase3clinical trial s, atotalof 564patientsweretreatedwithCIPRO' HCOTI C.Adverse events wi th at least remoterelationshipto treatment included headache(1.2%)and pruritus (0.4%). The following treatment -rel ated adverse events were each reported in a single patient: migrai ne, hypesthesia, paresthesia, fungaldermatitis, cough, rash, urticaria, and alopecia. NDC 0065-8531-10 CIPRO' is a registered trademark of BayerAG . Licensedby Bayer AG Manufactured by Bayer Corporation RxOnly U.S. Pat. Nos. 4,670,444; 4,844,902; 5,843,930;andPat. Pending. Revi sed January, 1999 CHCOB-0199
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